XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
   Pharmacotherapy
   Radiotherapy
   Vaccination
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Therapy Channel
subscribe to Therapy newsletter

Latest Research : Cancer : Therapy

   DISCUSS   |   EMAIL   |   PRINT
Oral chemotherapy option soon for cancer
Apr 18, 2006, 07:20, Reviewed by: Dr. Priya Saxena

"Full results from the study have been submitted to the American Society of Clinical Oncology (ASCO) for presentation at their annual meeting taking place from June 2-6 in Atlanta, the US,"

 
Swiss pharmaceutical major Roche's study investigating Xeloda (capecitabine) in the first-line treatment of advanced stomach cancer has successfully met its primary endpoint, the company said Monday.

Data from the first-ever phase III clinical study showed that Xeloda, added to another chemotherapy called cisplatin, was at least as effective as the current standard treatment - that uses intravenous 5-fluorouracil plus cisplatin - in terms of time to disease progression, Roche said in a statement.

This international study was a randomised, open-label one of the effect of first-line chemotherapy with Xeloda plus cisplatin versus intravenous 5-fluorouracil plus cisplatin on time to disease progression in patients with advanced or metastatic gastric cancer.

Gastric cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. It affects twice as many men as women and occurs more frequently in people aged over 55 years.

Xeloda is licensed in more than 90 countries including the EU, the US, Japan, Australia, Canada and India and has been shown to be an effective, safe, simple and convenient oral chemotherapy.

The oncology market in India is estimated at $30 million. Other cancer drugs from Roche in India include Herceptin and Avastin.

"Full results from the study have been submitted to the American Society of Clinical Oncology (ASCO) for presentation at their annual meeting taking place from June 2-6 in Atlanta, the US," the statement said.

Based on the results of the study, Roche plans to file for an indication in advanced gastric cancer with worldwide regulatory authorities, the company said.
 

- Indo-Asian News Service
 

 
Subscribe to Therapy Newsletter
E-mail Address:

 



Related Therapy News

Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart
Anti-cancer possibilities seen for certain monoamine oxidase inhibitors
AS101 protects the testis from the effects of paclitaxel
Microbeam Radiation Therapy (MRT) Could Improve Cancer Treatment
Novel EGFR antibody mAb 806 targets tumors but not normal tissues
Oral chemotherapy option soon for cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us